By Laura O’Brien, Ph.D., Boehringer Ingelheim Pharmaceuticals, Inc.; Nina Cauchon, Ph.D., R.A.C., Amgen Inc.; Willy Liou, M.S., R.A.C., Amgen Inc.; Tushar Mukherjee, Ph.D., Sandoz Inc.; and Satish Singh, Ph.D., Pfizer Inc.
With products ranging in scope and complexity, implementing even a streamline regulatory framework may be challenging.
Cover Story Sidebar
By Stefan Leiner, Ph.D., and Christoph Kreher, Ph.D., Boehringer Ingelheim Pharma GmbH & Co. KG
By Gary A. Thompson, Ph.D., FAAPS